RxDoctor Payments Data

Debra Booth

Psychiatric/Mental Health · Woburn, MANPI 1043846942

Payments from drug & device makers

$736in general payments, 2019–2025

Across 20 payments — averaging $36.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$151
  • Alkermes, Inc.$147
  • Otsuka America Pharmaceutical, Inc.$145
  • AbbVie$98
  • Lundbeck LLC$62
  • Neurocrine Biosciences, Inc.$50
  • plus $83 from 3 others

What the payments were for

  • Food & beverage$736100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$736 in reported general payments places this provider in the 70th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

See all psychiatric/mental health providers in Massachusetts

Medicare billing

Part B allowed, 2024
$76,518
Medicare patients
164
Services billed
847

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate27$223,032
Invega TrinzaPaliperidone Palmitate15$108,193
Invega SustennaPaliperidone Palmitate30$87,326
Lurasidone Hcl74$70,153
VraylarCariprazine Hcl35$56,563
Aripiprazole144$25,490
Clozapine436$23,667
ClozarilClozapine20$20,740
Paliperidone ErPaliperidone118$20,627
TrintellixVortioxetine Hydrobromide14$9,713
Clozapine OdtClozapine18$9,199
Divalproex Sodium ErDivalproex Sodium122$5,319
Olanzapine247$4,390
Risperidone163$4,342
Quetiapine Fumarate237$3,941

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$50$223,03227 claims
AbbVieVraylar$98$56,56335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

Other psychiatric/mental health in Woburn

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →